Safety
TRAEs, hyperlipidaemia, rash, hypothyroidism, skin depigmentation
HYPOTHYROIDISM, HYPERLIPIDAEMIA, SKIN DEPIGMENTATION
For the 119 patients who received at least one dose of Pucotenlimab, 98.3% reported TEAEs, 77.3% reported TRAEs, and 15.1% reported TRAEs of Grade ≥ 3. TRAEs of occurrence ≥ 10% were thyroid function test abnormal (26.1%), skin depigmentation (21.0%), rash (16.8%), aspartate aminotransferase increased (15.1%), hyperlipidaemia (13.4%), blood bilirubin increased (12.6%), alanine aminotransferase increased (12.6%), and hypothyroidism (12.6%) as shown in Table Safety profile of the patients who were given at least one dose of Pucotenlimab (